RxDoctor Payments Data

Simon Feng, MD

Pain Medicine · Greenwood, INNPI 1649274317

Payments from drug & device makers

$835in general payments, 2019–2025

Across 39 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$178
  • Orexo US, Inc.$138
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$106
  • Gilead$73
  • Pear Therapeutics (US), Inc.$62
  • Biodelivery Sciences International, Inc.$49
  • plus $228 from 9 others

What the payments were for

  • Food & beverage$835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835 in reported general payments places this provider in the 25th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$67,026
Medicare patients
97
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl52$33,486
OxycontinOxycodone Hcl79$21,769
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl189$16,111
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen735$15,358
NucyntaTapentadol Hcl24$13,722
SuboxoneBuprenorphine Hcl/Naloxone Hcl31$13,050
Buprenorphine43$11,855
Oxycodone Hcl665$11,577
Pregabalin158$10,414
Fentanyl42$9,964
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen391$7,281
Buprenorphine Hcl182$4,776
ButransBuprenorphine11$3,336
Gabapentin188$1,681
Naloxone Hcl37$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta$18$47,20876 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →